Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT05339581
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05322499
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT05320081
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Department of Hematology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT05225844
- Locations
- 🇨🇳
Harbin Medical University, Harbin, Heilongjiang, China
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 68
- Registration Number
- NCT05222035
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05213884
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Chongqing University Three Gorges Hospital, Wanzhou, Chongqing, China
🇨🇳The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 214
- Registration Number
- NCT05198609
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 77
- Registration Number
- NCT05193292
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05189483
- Locations
- 🇨🇳
Department of Bone and Soft Tissue, Henan Cancer Hospital, Zhengzhou, Henan, China
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT05183958
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.